Autolus Therapeutics PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Autolus Therapeutics reports its first commercial sales of AUCATZYL in the US, expands its CAR T-cell therapy pipeline for oncology and autoimmune diseases, and continues to incur significant losses.
NASDAQ
10-K: Autolus Therapeutics Achieves FDA Approval for AUCATZYL, Reports Full Year 2024 Financial Results
Autolus Therapeutics announces FDA approval for AUCATZYL and reports financial results for the year ended December 31, 2024, highlighting commercial launch preparations and pipeline development.
NASDAQ
Autolus Therapeutics submits a BLA to the FDA for obe-cel in r/r adult B-ALL and reports full year 2023 financial results.